ADAPY (Adaptimmune Therapeutics) ROE % Adjusted to Book Value: 0.00% (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Adaptimmune Therapeutics ROE % Adjusted to Book Value?

Adaptimmune Therapeutics ADAPY +5.80% ROE % Adjusted to Book Value is 0.00% as of Jun. 2025.

Adaptimmune Therapeutics's ROE % for the quarter that ended in Jun. 2025 was 0.00%. Adaptimmune Therapeutics's PB Ratio for the quarter that ended in Jun. 2025 was N/A. Adaptimmune Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2025 was N/A.

Adaptimmune Therapeutics ROE % Adjusted to Book Value Related Terms

Adaptimmune Therapeutics ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Adaptimmune Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adaptimmune Therapeutics ROE % Adjusted to Book Value Chart

Adaptimmune Therapeutics Annual Data
Trend Jun15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -22.84 -20.27 -39.24 -41.14 -23.55

Adaptimmune Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 177.98 -26.30 -55.21 0.00 0.00

ADAPY vs BCLI, APRE, JSPR: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Adaptimmune Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adaptimmune Therapeutics ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adaptimmune Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Adaptimmune Therapeutics's ROE % Adjusted to Book Value falls into.


Adaptimmune Therapeutics ROE % Adjusted to Book Value Calculation

Adaptimmune Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-275.74% / 11.71
=-23.55%

Adaptimmune Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 0.00% mean?
Adaptimmune Therapeutics (ADAPY) has a ROE % Adjusted to Book Value of 0.00% as of Jun. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Adaptimmune Therapeutics and its competitors.
Is Adaptimmune Therapeutics' ROE % Adjusted to Book Value too high?
Adaptimmune Therapeutics' current ROE % Adjusted to Book Value is 0.00%.
How does Adaptimmune Therapeutics' ROE % Adjusted to Book Value compare to BCLI and APRE?
Adaptimmune Therapeutics' ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Adaptimmune Therapeutics and its competitors. Adaptimmune Therapeutics's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adaptimmune Therapeutics stock overvalued right now?
Adaptimmune Therapeutics (ADAPY) has a current ROE % Adjusted to Book Value of 0.00%. The current ROE % Adjusted to Book Value is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Adaptimmune Therapeutics (ADAPY), the current ROE % Adjusted to Book Value is 0.00% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Adaptimmune Therapeutics Business Description

Other Exchanges 473A:Germany
Address 99 Park Drive, Milton Park, The Innovation Centre, Abingdon, Oxfordshire, GBR, OX14 4RY
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its product pipelines include ADP-600 [PRAME] and ADP-520 [CD70].